AR121598A1 - Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano - Google Patents

Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Info

Publication number
AR121598A1
AR121598A1 ARP210100669A ARP210100669A AR121598A1 AR 121598 A1 AR121598 A1 AR 121598A1 AR P210100669 A ARP210100669 A AR P210100669A AR P210100669 A ARP210100669 A AR P210100669A AR 121598 A1 AR121598 A1 AR 121598A1
Authority
AR
Argentina
Prior art keywords
methods
antibacterial agent
oxazolidinone compound
compound
oxazolidinone
Prior art date
Application number
ARP210100669A
Other languages
English (en)
Inventor
Brendan M Crowley
Philippe Nantermet
David B Olsen
Takao Suzuki
Lihu Yang
Lanying You
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR121598A1 publication Critical patent/AR121598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo.
ARP210100669A 2020-03-20 2021-03-17 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano AR121598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/080359 WO2021184339A1 (en) 2020-03-20 2020-03-20 Oxazolidinone compound and methods of use thereof as an antibacterial agent

Publications (1)

Publication Number Publication Date
AR121598A1 true AR121598A1 (es) 2022-06-22

Family

ID=75478174

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100669A AR121598A1 (es) 2020-03-20 2021-03-17 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Country Status (17)

Country Link
EP (1) EP4121058A1 (es)
JP (1) JP7241984B2 (es)
KR (1) KR20220156577A (es)
CN (1) CN115605208A (es)
AR (1) AR121598A1 (es)
AU (1) AU2021239937B2 (es)
BR (1) BR112022018674A2 (es)
CA (1) CA3172304A1 (es)
CL (1) CL2022002511A1 (es)
CO (1) CO2022013595A2 (es)
CR (1) CR20220472A (es)
EC (1) ECSP22073580A (es)
IL (1) IL296401A (es)
MX (1) MX2022011431A (es)
PE (1) PE20230002A1 (es)
TW (1) TWI799814B (es)
WO (2) WO2021184339A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016063A (es) 2020-06-18 2023-04-11 Akagera Medicines Inc Compuestos de oxazolidinona, composiciones de liposomas que comprenden compuestos de oxazolidinona y metodos de uso de los mismos.
WO2023102363A1 (en) * 2021-11-30 2023-06-08 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
WO2024035618A1 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Processes for preparing oxazolidinone compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
MXPA03003473A (es) * 2000-10-17 2003-08-19 Upjohn Co Metodos para producir compuestos de oxazolidinona.
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0108764D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
AR038576A1 (es) * 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
WO2005113520A1 (en) * 2004-05-20 2005-12-01 Pharmacia & Upjohn Company Llc Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
JP2008508271A (ja) 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその化合物を製造および使用する方法
WO2006059221A2 (en) * 2004-12-03 2006-06-08 Pharmacia & Upjohn Company Llc Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
WO2006079896A2 (en) * 2005-01-27 2006-08-03 Pharmacia & Upjohn Company Llc Stable polyol formulations of oxazolidinone antibacterial agents
CN102131811A (zh) 2008-06-24 2011-07-20 财团法人乙卯研究所 具有稠合环的*唑烷酮衍生物
US20110190199A1 (en) * 2008-09-03 2011-08-04 Pfizer Inc. Combination Therapy for Tuberculosis
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
EP3307268B1 (en) * 2015-07-17 2021-09-01 The Global Alliance for TB Drug Development, Inc. Substituted phenyloxazolidinones for antimicrobial therapy
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2018170664A1 (en) * 2017-03-20 2018-09-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
WO2021184339A1 (en) 2021-09-23
CR20220472A (es) 2022-11-14
CA3172304A1 (en) 2021-09-23
EP4121058A1 (en) 2023-01-25
IL296401A (en) 2022-11-01
WO2021188606A1 (en) 2021-09-23
BR112022018674A2 (pt) 2022-11-01
MX2022011431A (es) 2022-10-03
KR20220156577A (ko) 2022-11-25
AU2021239937B2 (en) 2023-10-26
TW202200573A (zh) 2022-01-01
CL2022002511A1 (es) 2023-03-24
JP7241984B2 (ja) 2023-03-17
AU2021239937A1 (en) 2022-10-06
ECSP22073580A (es) 2022-11-30
PE20230002A1 (es) 2023-01-05
TWI799814B (zh) 2023-04-21
JP2023507683A (ja) 2023-02-24
CO2022013595A2 (es) 2023-02-16
CN115605208A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
AR121598A1 (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
AR109452A1 (es) Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
GEP20237506B (en) Pcsk9 antagonist compounds
AR116283A1 (es) Inhibidores del sarcómero cardíaco
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
PE20221504A1 (es) Derivados de un inhibidor de fgfr
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR121226A1 (es) Compuestos y usos de estos
CL2020002891A1 (es) Nuevos derivados de quinolina
CL2020000553A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
AR110770A1 (es) Moduladores del canal de potasio
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
EA202092579A1 (ru) Оксозамещенное соединение
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos